Navigation Links
Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT)
Date:7/10/2014

t patients or discharge them on outpatient therapy.
  • Preference for oral antibiotics over OPAT: Oral therapies offer the potential to substantially simplify antibiotic treatment compared with therapies that are administered intravenously. Not surprisingly, surveyed ID specialists reported being more likely to prescribe oral formulations of both Cubist's Sivextro (tedizolid) and Tetraphase's emerging drug eravacycline when discharging patients than OPAT with either drug, suggesting oral formulations of these agents will see greater use as discharge therapy.
  • Comments from Decision Resources Group Analyst Hannah E. Cummings, Ph.D.:

    • "Hospitals are actively looking to cut costs and reduce or shorten admissions, and discharging patients on OPAT is an important part of their strategy. OPAT is a particularly attractive treatment modality for patients presenting to the emergency room with an infection requiring IV antibiotic therapy but not necessitating admission. ID specialists and emergency room physicians are frequently involved in identifying and recommending patients for OPAT and will likely be key stakeholders in driving uptake of new OPAT therapies."
    • "Surveyed ID specialists identified a need for new OPAT drugs for infections due to drug-resistant pathogens that are dosed once daily. Although the OPAT market is highly genericized, agents demonstrating benefits in efficacy, dosing-frequency and/or administration, such as Cubist's Cubicin (daptomycin) and Merck's Invanz (ertapenem), have experienced widespread use in the OPAT market. New agents will also have to demonstrate improvements on these key attributes to successfully compete in the OPAT market segment."

    About Decision Resources Group
    Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare indu
    '/>"/>

    SOURCE Decision Resources Group
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. Janssen R&D Ireland Announces Agreement with PATH for Early Development of Rilpivirine in Long-Acting Formulation for Potential Prophylactic Intervention
    2. Beyond the Headlines: What the FDA Decisions on Extended-release and Long-Acting Opioids Mean for People With Pain
    3. WomanCare Global launches Simplant, Long-acting Reversible Contraception, in Chile
    4. PROLOR Biotech To Present Preclinical Data On Its Long-Acting Clotting Factor Vlla At 2012 ASH Annual Meeting
    5. Study Published In Contraception Evaluates Medical Expenditures For Unintended Pregnancies And Potential Cost Impact Of Increased Use Of Long-Acting Reversible Contraception
    6. Purdue Pharma L.P. Comments on FDA Announcement on REMS for Extended-Release and Long-Acting Opioid Analgesics
    7. Applegate CEO Worries FDA Plan To Address Antibiotics In Animal Agriculture Is Too Little, Too Late
    8. AVMA lauds FDA for new regulation of antibiotics in livestock feed
    9. Debiopharm Group and TCG Lifesciences Ltd. Enter into an Exclusive Research Agreement to Develop a Novel Class of Antibiotics, a New Strategic Therapeutic Area for Debiopharm
    10. Rising Drug Resistance is Driving Early-Line Use of Powerful Antibiotics Such as Carbapenems for Gram-Negative Infections, According to Surveyed EU5 Physicians
    11. Antibiotic Resistance 2013: The Antibiotics Development Pipeline and Strategies to Combat Antibiotic Resistance
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/1/2015)...  Thoratec Corporation (NASDAQ: THOR ), a world leader ... failing hearts, announced today that Marta Antonucci has ... This new Europe -based position ... North America , including Europe ... America , and reports directly to the Chief Executive ...
    (Date:5/1/2015)... May 1, 2015 Braeburn Pharmaceuticals ... current therapeutic focus beyond addiction and pain ... disorders. Braeburn has acquired an implantable, six-month ... risperidone for treatment of schizophrenia from Endo ... global rights to other potential applications of ...
    (Date:5/1/2015)... 2015 Pharmacyclics, Inc. (the "Company") (NASDAQ: ... ended March 31, 2015, as well as general business ... conference call will be held. Key Highlights ... 31, 2015 increased to $206 million from $119 million ... Worldwide IMBRUVICA ® (ibrutinib) net product revenue of ...
    Breaking Medicine Technology:Thoratec Announces Addition To Senior Management Team 2Thoratec Announces Addition To Senior Management Team 3Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 2Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 3Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 4Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 2Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 3Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 4Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 5Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 6Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 7Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 8Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 9Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 10Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 11Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 12Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 13Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 14Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 15Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 16Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 17Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 18Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 19Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 20Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 21Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 22Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 23Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 24Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 25Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 26Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 27Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 28Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 29Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 30Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 31
    ... Onset and Total,Sleep Time, and key secondary endpoints, including ... Evotec to host a,conference call at 4pm CET (3pm ... OXFORD, England, June 4, 2007-- Evotec AG,(Frankfurt Stock Exchange: ... II clinical trial of EVT 201 in,patients with chronic ...
    ... Placebo-controlled Trial,Ever Conducted in CTCL Presented at ... 04, 2007 /PRNewswire/ -- Preliminary results of,the ... patients with cutaneous T-cell lymphoma (CTCL) showed,that ... as placebo in eliciting,a clinical response in ...
    Cached Medicine Technology:Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ... 2Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ... 3Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ... 4Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 2Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 3Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 4Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 5Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 6
    (Date:5/3/2015)... San Mateo, CA (PRWEB) May 03, 2015 ... newest service, MnemeTherapy® at two upcoming area seminars. The ... during the PSA Annual Regional Stroke Conference to be ... will be offered on Wednesday, May 13 during the ... Crowne Plaza. , “These seminars offer an excellent ...
    (Date:5/3/2015)... May 03, 2015 HealthPostures, a ... solutions, announces its appearance at the , May 5 ... that HealthPostures will exhibit at the conference include its ... sit stand solutions is the 6100 TaskMate Executive. Features ... control, an adjustable keyboard tray, extended platform work surface ...
    (Date:5/2/2015)... BC (PRWEB) May 02, 2015 Vancouver fencing ... will now provide valuable advice to prospective clients related to ... are looking to install railings around their decks and patios. ... several questions that pop up once the person rolls up ... phases of installing a railing in finding a gate that ...
    (Date:5/2/2015)... NY (PRWEB) May 02, 2015 It’s ... a deadly natural disaster strikes anywhere on this planet, ... leverage human sympathy and compassion for their own personal ... States Computer Emergency Readiness Team) issued an alert ... “of potential email scams citing the earthquake in Nepal. ...
    (Date:5/2/2015)... 02, 2015 On Tuesday April 7th, ... (ELCH) gathered to celebrate improvements in patient care. In ... Partners (RVHP), had zero acquired ventilator associated infections, zero ... infections. ELCH was also recently named a Top Performer ... at ELCH credited the teamwork of staff from all ...
    Breaking Medicine News(10 mins):Health News:NuevaCare Introduces MnemeTherapy® Approach to Care for Elderly Patients with Alzheimer’s, Stroke and Other Types of Neurodegenerative Conditions 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 3Health News:Professional Staff at QS Fencing Company Now Provides Advice on Railings and Gates 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 3Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 4Health News:East Liverpool City Hospital Celebrates Patient Care Improvements 2
    ... Carbon monoxide poisoning is a serious threat, especially during the ... keep warm, says the American College of Emergency Physicians. ... precautionary steps or notice the symptoms. Thinking about it now ... may save your life and the lives of those around ...
    ... , MONDAY, Dec. 27 (HealthDay News) -- ... heart rhythms that can cause heart damage and sudden ... worldwide and found variants in 22 locations across the ... measure of electrical depolarization in the heart,s lower chambers ...
    ... potential therapy based on a natural human protein significantly slows ... same genetic mutation as boys with the most common form ... 27 in the Proceedings of the National Academy of ... mutation in about one of every 3,500 boys. They are ...
    ... from the University of Pennsylvania School of Medicine and Utrecht ... branch of the immune response. This system, called complement, comprises ... in destroying foreign invaders. It serves as a rapid defense ... In a study published in the December 24 issue of ...
    ... , SATURDAY, Dec. 25 (HealthDay News) -- For allergy sufferers ... relief from respiratory symptoms, an expert suggests. Dust from ... plants and more can cause all sorts of breathing problems, ... in Melrose Park, Ill. In a news release from Loyola ...
    ... By Dennis Thompson HealthDay Reporter , MONDAY, Dec. ... that she had cataracts in both eyes. "They saw them ... surgery then," Norred, now 74 and living in Oklahoma City, recalled. ... both eyes in the spring -- the right eye on May ...
    Cached Medicine News:Health News:Carbon Monoxide May Be Greater Threat in Winter 2Health News:Human protein improves muscle function of muscular dystrophy mice 2Health News:Structure of key molecule in immune system provides clues for designing drugs 2Health News:Structure of key molecule in immune system provides clues for designing drugs 3Health News:Have an Allergy-Free Holiday and a Happier New Year 2Health News:Have Cataracts? Get Surgery, Woman Urges 2
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    Medicine Products: